---
title: "Welcure Drugs & Pharmaceuticals Ltd (524661) — Share Price, Financials & Analysis"
symbol: "524661"
company: "Welcure Drugs & Pharmaceuticals Ltd"
canonical: "https://tapetide.com/stocks/524661"
isin: "INE331C01025"
nse_symbol: "WELCUREDRUGSPHARMACEUTICALSLTD"
bse_code: "524661"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 28.44
generated_at: "2026-09-13T18:58:44.675Z"
---

# Welcure Drugs & Pharmaceuticals Ltd (524661)

Canonical page: https://tapetide.com/stocks/524661

## Company

- **NSE Symbol:** WELCUREDRUGSPHARMACEUTICALSLTD
- **BSE Code:** 524661
- **ISIN:** INE331C01025
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Face Value:** ₹1
- **F&O Eligible:** No

## About

Incorporated in 1992, Welcure Drugs and Pharmaceuticals Ltd is in the business of pharmaceutical and healthcare.[1]

## Latest Price

## Key Fundamentals

Observed at 2026-09-11T04:38:41.503287Z.

- **Market Cap:** ₹28.44 Cr
- **Classification:** Microcap
- **P/E (reported):** -5.5
- **EPS (TTM):** ₹-0.13
- **Book Value:** ₹0.79
- **Price to Book:** 0.28
- **Dividend Yield:** 0%
- **ROE:** 2.12%
- **ROCE:** 1.23%
- **Debt to Equity:** 0
- **Revenue (yearly):** ₹365.54 Cr
- **Net Income:** ₹-5.49 Cr
- **EBITDA:** ₹-6.93 Cr
- **52-Week High:** ₹0.89
- **52-Week Low:** ₹0.19
- **RSI (14):** 44.31

## Tapetide Score

- **Score:** 55 / 100
- **Score date:** 2026-09-04
- **Archetype:** No Dominant Pattern
- **What it means:** The three pillars do not combine into a recognisable pattern. Read them individually rather than looking for one story — the lack of a pattern is itself the finding.
- **Pillar profile:** Quality: Average · Valuation: Cheap · Momentum: Falling
- **Percentile:** 70.1 (of 4473 scored stocks)
- **Confidence:** 88%
- **Data coverage:** 76%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 43.92 | 9% |
| growth | 98.9 | 9% |
| momentum | 17.11 | 12% |
| ownership | 50 | 24% |
| quality | 55.48 | 22% |
| valuation | 70.91 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company has reduced debt.
- Company is almost debt free.
- Stock is trading at 0.28 times its book value

### Weaknesses

- Company has low interest coverage ratio.
- Company has a low return on equity of -2.28% over last 3 years.
- Company has high debtors of 213 days.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| ebitda margin growth | — | -117.93% | -98.72% | -108.41% |
| net income growth | — | -349.55% | — | — |
| revenue growth | -100% | — | — | 390% |
| roce | — | -109.43% | -81.67% | 19.94% |
| roe | — | -116.26% | -1.4% | -97.33% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 0 | 0 | 0 | 0 | 0 | 25 | 1 | 21 | 300 | 66 | 0 | 0 |
| Expenses | 0 | 0 | 0 | 0 | 0 | 23 | 1 | 21 | 269 | 54 | 0 | 50 |
| Operating Profit | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 31 | 11 | 0 | -50 |
| OPM % | — | — | — | — | — | 7 | 10 | 3 | 10 | 17 | — | — |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 3 | 31 | 11 | 1 | -50 |
| Tax % | 0 | 0 | 0 | 0 | 0 | 0 | 56 | 0 | 25 | 25 | 25 | 0 |
| Net Profit | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 3 | 23 | 8 | 1 | -50 |
| EPS in Rs | 0 | -0.01 | 0 | 0 | -0.02 | 0.01 | 0 | 0.02 | 0.19 | 0.07 | 0.01 | -0.4 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 366 |
| Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 24 | 372 |
| Operating Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | -7 |
| OPM % | 33 | -40 | 0 | -12 | 46 | 18 | — | — | 4 | -1.9 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | -5 |
| Tax % | 0 | 0 | — | 0 | 0 | 0 | 0 | 0 | 22 | 0 |
| Net Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | -5 |
| EPS in Rs | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | -0.01 | 0.02 | -0.04 |
| Dividend Payout % | 0 | 0 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 12 | 12 | 12 | 12 | 12 | 12 | 13 | 13 | 112 | 124 |
| Reserves | -12 | -12 | -12 | -12 | -12 | -12 | -12 | -12 | -10 | -27 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 123 | 0 |
| Other Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 41 | 413 |
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 267 | 510 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Other Assets | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 267 | 509 |
| Total Assets | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 267 | 510 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -222 | 2 |
| Cash from Investing Activity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 |
| Cash from Financing Activity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 222 | 0 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -222 | 2 |
| CFO/OP | 67 | 50 | — | 100 | 67 | 100 | -79 | 57 | -22890 | -25 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 0 | 0 | 0 | 0 | 0 | 0 | — | — | 282 | 213 |
| Inventory Days | — | — | — | — | — | — | — | — | 2554 | 162 |
| Days Payable | — | — | — | — | — | — | — | — | 52 | 226 |
| Cash Conversion Cycle | 0 | 0 | 0 | 0 | 0 | 0 | — | — | 2784 | 150 |
| Working Capital Days | 81 | 73 | 46 | 0 | 0 | 0 | — | — | 2092 | -56 |
| ROCE % | 120 | -67 | 0 | -40 | 133 | 25 | 10 | -13 | 3 | -3 |

## Shareholding Pattern

### Quarterly

| Category | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 93.68% | 94.28% | 93.87% | 93.69% | 93.14% | 93.55% | 98.79% | 98.99% | 98.74% | 91.83% | 94.41% | 95.63% |
| Others | 6.32% | 5.72% | 6.13% | 6.31% | 6.86% | 6.45% | 1.21% | 1.01% | 1.26% | 8.17% | 5.59% | 4.37% |
| No. of Shareholders | 29251 | 29593 | 29957 | 31530 | 31045 | 30218 | 30605 | 32366 | 37298 | 76954 | 87288 | 87977 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 1 / 7 / 11

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 0.23 | Sell |
| EMA (10) | 0.23 | Sell |
| SMA (20) | 0.23 | Sell |
| EMA (20) | 0.23 | Sell |
| SMA (50) | 0.24 | Sell |
| EMA (50) | 0.24 | Sell |
| SMA (100) | 0.26 | Sell |
| EMA (100) | 0.26 | Sell |
| SMA (200) | 0.31 | Sell |
| EMA (200) | 0.36 | Sell |

### Oscillators — summary: **Neutral**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 44.31 | Neutral |
| MACD (12,26,9) | 0 | Sell |
| Stochastic (14,3,3) | 55.56 | Neutral |
| ADX (14) | 23.92 | Neutral |
| Williams %R (14) | -50 | Neutral |
| ATR (14) | 0.02 | High Volatility |
| ROC (12) | 4.76 | Buy |
| Stoch RSI (14) | 55.58 | Neutral |
| UO (7,14,28) | 31.06 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-07-14 | [Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Of Welcure Drugs & Pharmaceuticals Ltd Held On Today I.E. Tuesday 14Th July 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=94c77f7b-f254-4359-8b05-6e71ea647d78.pdf) |
| 2026-06-19 | [Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Of Welcure Drugs & Pharmaceuticals Limited Held On Today I.E. Friday 19Th June 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2f3f54bf-93c3-4c49-ab32-07ce6322a73a.pdf) |
| 2026-06-19 | [Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f0c0fbf1-b610-4bba-a8c0-01bfb22cd180.pdf) |
| 2026-06-01 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d9ea8bd0-7743-4a88-8ac6-c002b544c02b.pdf) |
| 2026-05-30 | [Compliances-Reg.24(A)-Annual Secretarial Compliance](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=36936b17-0852-4f15-835b-30f1d48547f4.pdf) |
| 2026-05-29 | [Board Meeting Outcome for Outcome Of The Meeting Of Board Of Directors Of The Welcure Drugs And Pharmaceuticals Limited Held Today I.E. Friday 29Th May 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7b27bb2d-a3a9-4faa-a871-07017c8ba8a6.pdf) |
| 2026-05-22 | [Board Meeting Intimation for Consideration And Approval Of The Audited Financial Results For The Quarter/Year Ended 31St March 2026 Along With Statement Of Assets And Liabilities And Cash Flow Statement For The Year Ended 31St March 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=568b5dce-3ed8-4c1e-81ba-d4de144ef7e4.pdf) |
| 2026-04-23 | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0c8db819-51e5-481f-9690-8d92c2292942.pdf) |
| 2026-04-03 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=54edd60f-716b-4354-9635-a7c35a8a127f.pdf) |
| 2026-03-26 | [Closure of Trading Window](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9b62b9d2-598b-4971-beec-e46f5b128047.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-05-29 | [Audited Standalone Financial Result For The Quarter And Year Ended 31St March 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=86f2b8ef-ca68-4f15-ac0e-572a22982d2f.pdf) |
| 2026-02-12 | [Unaudited Financial Results For The 3Rd Quarter Ended On 31St December 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4a0a2b2e-b984-4634-8c17-528bc885673b.pdf) |
| 2025-11-13 | [Result- Unaudited Financial Statement For The Quarter And Half Year Ended 30Th September 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8b2b05e1-c4af-45e1-98dc-2f20f7c55e0c.pdf) |
| 2025-08-05 | [Standalone Unaudited Financial Results For The 1St Quarter Ended 30Th June 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9f0d2f47-a228-4203-8f36-2ecf5e2b8d49.pdf) |
| 2025-05-29 | [Audited Standalone Financial Results And Audited Standalone Financial Statements Along With AuditorS Report Of The Company For The Quarter And Year Ended March 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b30dfdcd-9617-4caa-8c59-65bce395ae71.pdf) |
| 2025-02-14 | [Outcome Of The Meeting Of The Board Of Directors Of Welcure Drugs & Pharmaceuticals Limited Held On Today I.E. Friday 14 February 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f974f501-cb6f-4d30-8fde-417fcbd42462.pdf) |
| 2024-11-14 | [Unaudited Financial Results Of The Company Along With TheLimited Review Report As Issued By Statutory Auditor Of The Company For The 2Nd Quarter And HalfYear Ended On 30Th September 2024.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d4c182ce-de31-4886-b801-993d1d0946d1.pdf) |
| 2024-08-14 | [Quarterly Unaudited Financial Results Of June 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=38bcf30c-ff3b-4e2d-9ce1-d239f83051ab.pdf) |
| 2024-07-02 | [Revised Audited Standalone Financial Statements Of The Company For The Year Ended March 31,2024.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=916b7b6d-6845-4e17-a74b-d8fed36ee293.pdf) |
| 2024-06-25 | [Revised Audited Standalone Financial Results For The Quarter And Financial Year Ended 31St March, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9321325c-730c-434a-8fee-c688cca47ea0.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 7 Feb - Board meeting on Feb 12, 2026 to approve unaudited Q3/9M results ended Dec 31, 2025. | [Board Meeting Intimation for Intimation Of Meeting Of The Board To Be Held On Thursday, February 12, 2026. 7 Feb - Board meeting on Feb 12, 2026 to approve unaudited Q3/9M results ended Dec 31, 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/20d511f0-acb8-41cc-9fcd-ef1356b1a3cb.pdf) |
| 5 Jan - Certificate under Regulation 74 (5) of SEBI (DP) Regulations, 2018 for the 3rd Quarter ended 31st December, 2025. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 5 Jan - Certificate under Regulation 74 (5) of SEBI (DP) Regulations, 2018 for the 3rd Quarter ended 31st December, 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/33c844b8-d85f-4725-a3cd-29a059b70425.pdf) |
| 3 Feb - Executed agreements to sell Kolkata SEZ TechPark II (~1,054,357 sqft) for ₹409.86cr and 17.75-acre land for ₹260cr. | [Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 3 Feb - Executed agreements to sell Kolkata SEZ TechPark II (~1,054,357 sqft) for ₹409.86cr and 17.75-acre land for ₹260cr.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3f601590-0acf-41a2-b891-b5e0df341b3e.pdf) |
| 3 Apr - Certificate under Regulation 74(5) of SEBI (Depository and Participants) Regulations, 2018 for the 4th Quarter and Annual year ended 31st MArch, 2026. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 3 Apr - Certificate under Regulation 74(5) of SEBI (Depository and Participants) Regulations, 2018 for the 4th Quarter and Annual year ended 31st MArch, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/54edd60f-716b-4354-9635-a7c35a8a127f.pdf) |
| 26 Mar - Trading window closed from April 1, 2026 until 48 hours after audited results for year ended March 31, 2026. | [Closure of Trading Window 26 Mar - Trading window closed from April 1, 2026 until 48 hours after audited results for year ended March 31, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9b62b9d2-598b-4971-beec-e46f5b128047.pdf) |
| 26 Feb - DLF executives attended 'Chasing Growth 2026' investor meeting, Mumbai, 26 Feb 2026; no UPSI shared. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 26 Feb - DLF executives attended 'Chasing Growth 2026' investor meeting, Mumbai, 26 Feb 2026; no UPSI shared.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6f27af19-886d-47f4-a710-0e879a11797c.pdf) |
| 23 Jan - Publication of extracts of Unaudited Financial Results for Q3FY26 | [Announcement under Regulation 30 (LODR)-Newspaper Publication 23 Jan - Publication of extracts of Unaudited Financial Results for Q3FY26](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a8fb9236-6b6c-4d0d-ad01-fd6dd26af791.pdf) |
| 23 Jan - Earnings webcast recording for Q3 and nine months ended 31 Dec 2025 available online (23 Jan 2026). | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 23 Jan - Earnings webcast recording for Q3 and nine months ended 31 Dec 2025 available online (23 Jan 2026).](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3f10d44d-bea1-4e96-82bb-02bc2320087d.pdf) |
| 23 Feb - The executive(s) of the Company will participate in the investor conference scheduled on 26th February 2026 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 23 Feb - The executive(s) of the Company will participate in the investor conference scheduled on 26th February 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e935b4d4-4742-4b5e-aec3-f636f8b500f9.pdf) |
| 23 Apr - Company confirmed it is not a Large Corporate for FY2026. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 23 Apr - Company confirmed it is not a Large Corporate for FY2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0c8db819-51e5-481f-9690-8d92c2292942.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Oct 2024 | [Concall - Oct 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/479f23c9-a6ca-4bc6-ad23-822fa3044506.pdf) |
| Oct 2022 | [Concall - Oct 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/17c8917c-073c-4f16-8e14-758060bd163c.pdf) |
| Oct 2021 | [Concall - Oct 2021](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5cfb7a31-1e6a-46fc-b545-af5df9db4f1b.pdf) |
| Oct 2021 | [Concall - Oct 2021](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d5cc1280-d82a-4912-945b-f42868dba9e1.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f2b45f4c-9a3c-4720-ba4a-8f03bf972344.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/aa02509a-90e4-4797-b7f2-1c867cb0cfc7.pdf) |
| Nov 2020 | [Concall - Nov 2020](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f736cd12-d3b3-4447-a012-09249c2cc18f.pdf) |
| Nov 2019 | [Concall - Nov 2019](https://www.bseindia.com/xml-data/corpfiling/AttachHis/006362da-c193-4bec-8a3b-2fbb43a7ba22.pdf) |
| Nov 2018 | [Concall - Nov 2018](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2018/11/7408eaa9-5e52-482c-81fc-b4c9b257abc0.pdf) |
| Nov 2017 | [Concall - Nov 2017](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2017/11/1fc515ad-dfbb-4d54-bfa9-e5d36209a9f2.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Financial Year 2012 from nse](https://archives.nseindia.com/annual_reports/AR_DLF_2011_2012_14082012023433.zip) |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3bc3c50d-f5d6-41eb-bba8-8aee5b7978a4.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3ef8860c-fa8a-4778-9f29-8cb7d9b66688.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7b4e6db4-6c28-43e5-a871-b7dfe76ebeb4.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c74ae454-7c26-4a71-9407-843af250f1df.pdf) |
| from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/80889d6c-c7d4-49c4-aa3c-17fe5cee5f38.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/537b944d-0289-496d-a888-d766a328d245.pdf) |
| from bse | [Financial Year 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/532868/73790532868.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/524661/73019524661.pdf) |
| from bse | [Financial Year 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/532868/69373532868.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:58:44.675Z.